Want to see PRPO full AI Analyst Report?
Precipio (PRPO) AI Stock Analysis
Precipio
(NASDAQ:PRPO)
Improving revenue, cash generation, EBITDA, and the latest earnings-call momentum are the primary strengths. However, persistent net losses, weak technical trends, negative valuation support, and execution risk materially limit the score.
Precipio (PRPO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $32.40M
- Dividend Yield
- ―
- Average Volume (3M)
- 105.56K
- Price to Earnings (P/E)
- -27.8
- Beta (1Y)
- 0.56
- Revenue Growth
- 28.04%
- EPS Growth
- 43.26%
- Country
- US
- Employees
- 61
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Precipio Business Overview & Revenue Model
Company Description
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood ca...
Precipio Earnings Call Summary
The call presented multiple meaningful operational and financial improvements: record quarterly revenue (> $7M), strong product revenue acceleration (+35% sequential, +21% vs prior record), positive adjusted EBITDA (~$400K) and $700K operating cash generation leading to a >$3M cash balance. These positives are tempered by modest pathology sequential growth, prior distributor complexity that slowed past ramping, quarter-to-quarter timing/seasonality effects, noted execution risk to convert the expanded pipeline, and an unexplained spike in share trading. On balance, the company emphasized organic improvement and execution plans to sustain growth.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Guidance for the second half of 2026 centers on continued revenue growth from the Q2 momentum (Q2 topline >$7.0M, up ~22% YoY from $5.7M and up from ~$6.7M in Q1), with particular emphasis on accelerating product revenue (Q2 products ~$900K, +35% QoQ and ~21% above the prior ~$750K record) by converting the expanded commercial pipeline (added ~10 distributor reps, >25 new qualified customers, and >30 meetings in Q2) into active accounts; management expects this to drive operating leverage—building on the Q2 adjusted EBITDA of ~$400K (vs -$200K in Q1, a ~$600K swing driven by ~$300K revenue increase and ~$200K lower stock‑based comp)—and continued cash generation (operating cash flow ~$700K in Q2, ~10% of topline), with cash on hand >$3M (up ~$0.5M this quarter vs ~$1.1M a year ago) without raising capital.
Precipio Financial Statement Overview
Summary
Revenue growth, improving margins, positive EBITDA, stronger cash flow, and low-to-moderate leverage support the score. Persistent net losses, negative returns, equity erosion, and only recently sustained positive cash flow remain significant risks.
Income Statement
52NeutralBalance Sheet
60NeutralCash Flow
68Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.46M | 24.05M | 15.96M | 15.20M | 9.41M | 8.85M |
| Gross Profit | 12.00M | 10.71M | 7.56M | 6.02M | 2.51M | 2.39M |
| EBITDA | 600.00K | 1.46M | -2.70M | -4.32M | -10.65M | -7.05M |
| Net Income | -1.22M | -363.00K | -4.29M | -5.85M | -12.20M | -8.55M |
Balance Sheet | ||||||
| Total Assets | 21.32M | 21.32M | 17.00M | 18.10M | 21.50M | 30.44M |
| Cash, Cash Equivalents and Short-Term Investments | 3.08M | 6.04M | 1.39M | 1.50M | 3.44M | 11.67M |
| Total Debt | 3.34M | 3.65M | 1.25M | 1.12M | 1.39M | 1.43M |
| Total Liabilities | 6.56M | 6.76M | 4.90M | 3.67M | 5.14M | 5.83M |
| Stockholders Equity | 14.76M | 14.56M | 12.09M | 14.43M | 16.30M | 24.56M |
Cash Flow | ||||||
| Free Cash Flow | 789.00K | 359.00K | 216.00K | -3.69M | -8.00M | -7.26M |
| Operating Cash Flow | 1.10M | 685.00K | 439.00K | -3.56M | -7.72M | -6.58M |
| Investing Cash Flow | -311.00K | -326.00K | -223.00K | -126.00K | -277.00K | -682.00K |
| Financing Cash Flow | 1.16M | 903.00K | -329.00K | 1.74M | -225.00K | 16.27M |
Precipio Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRPO, the sentiment is Negative. The current price of 18.10 is below the 20-day moving average (MA) of 21.42, below the 50-day MA of 24.58, and below the 200-day MA of 24.99, indicating a bearish trend. The MACD of -1.56 indicates Positive momentum. The RSI at 25.39 is Positive, neither overbought nor oversold. The STOCH value of 6.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRPO.
Precipio Risk Analysis
Precipio disclosed 62 risk factors in its most recent earnings report. Precipio reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksPrecipio Peers Comparison
Overall Rating
NTRA67Neutral
BDSX62Neutral- PRPO56Neutral
GH55Neutral
NEO54Neutral
MYGN52Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| NTRA | 67Neutral | $59.72B | -304.63 | -11.73% | ― | 37.82% | 28.02% |
| BDSX | 62Neutral | $245.37M | -7.33 | -788.19% | ― | 34.46% | 43.48% |
| PRPO | 56Neutral | $32.40M | -27.85 | -8.49% | ― | 28.04% | 43.26% |
| GH | 55Neutral | $23.99B | -51.23 | 211.46% | ― | 42.74% | -4.60% |
| NEO | 54Neutral | $2.25B | -70.42 | -3.97% | ― | 11.08% | 71.76% |
| MYGN | 52Neutral | $607.38M | -5.32 | -32.59% | ― | -3.16% | 72.02% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PRPO | Precipio | 18.10 | -1.87 | -9.36% | |
| MYGN | Myriad Genetics | 6.35 | -1.83 | -22.37% | |
| NEO | NeoGenomics Inc. | 17.38 | 7.60 | 77.71% | |
| NTRA | Natera Inc. | 414.30 | 216.07 | 109.00% | |
| GH | Guardant Health | 178.80 | 79.88 | 80.75% | |
| BDSX | Biodesix, Inc. | 23.25 | 16.91 | 266.80% |
Precipio Corporate Events
Precipio Announces Q3 2026 Shareholder Update Call
PositiveSpecialty cancer diagnostics company Precipio, Inc. said on October 28, 2026, that it will host its Q3 2026 shareholder update call on November 10, 2026, at 5:00 p.m. ET, covering performance across its core businesses and featuring a moderated live...
Precipio Schedules Q2 2026 Shareholder Update Call
PositiveOn July 31, 2026, New Haven-based Precipio, Inc. announced it would host its Q2 2026 shareholder update call on August 17, 2026, at 5:00 p.m. ET to discuss performance across its core cancer diagnostics businesses. The call will feature prepared rema...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026